Aduro BioTech, Inc. operates as a clinical-stage immunotherapy company, which focuses on the discovery, development and commercialization of therapies that transform the treatment of challenging diseases. Its technology platforms include LADD, STING Pathway Activator and B-select monoclonal antibodies. The company was founded in 2000 and is headquartered in Berkeley, CA.
